Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial

被引：0

作者：

Hua Jin

Yu Zhang

Sijian Yu

Xin Du

Na Xu

Ruoyang Shao

Dongjun Lin

Yanqiu Chen

Jie Xiao

Zhiqiang Sun

Lan Deng

Xinquan Liang

Hongyu Zhang

Ziwen Guo

Min Dai

Pengcheng Shi

Fen Huang

Zhiping Fan

Zhao Yin

Li Xuan

Ren Lin

Xuejie Jiang

Guopan Yu

Qifa Liu

机构：

[1] Southern Medical University,Department of Hematology, Nanfang Hospital

[2] The First Affiliated Hospital of Shenzhen University,Department of Hematology and Shenzhen Bone Marrow Transplantation Public Service Platform, Shenzhen Second People’s Hospital

[3] The Seventh Affiliated Hospital of Sun Yat-Sen University,Department of Hematology

[4] Maoming People’s Hospital,Department of Hematology

[5] Sun Yat-Sen University,Department of Hematology, Sun Yat

[6] Southern Medical University,Sen Memorial Hospital

[7] Shanghai Jiao Tong University School of Medicine,Department of Hematology, Shenzhen Hospital

[8] The First People’s Hospital of Chenzhou,Department of Hematology, Shanghai Ninth People’s Hospital

[9] Peking University Shenzhen Hospital,Department of Hematology

[10] Zhongshan City People’s Hospital,Department of Hematology

[11] Guangdong Provincial Key Laboratory of Digital Medicine and Biomechanics,Department of Hematology

来源：

Journal of Hematology & Oncology | / 16卷

关键词：

Venetoclax; Azacitidine; Homoharringtonine; Relapsed; Refractory; Acute myeloid leukemia;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Jin, Hua
Zhang, Yu
Yu, Sijian
Du, Xin
Xu, Na
Shao, Ruoyang
Lin, Dongjun
Chen, Yanqiu
Xiao, Jie
Sun, Zhiqiang
Deng, Lan
Liang, Xinquan
Zhang, Hongyu
Guo, Ziwen
Dai, Min
Shi, Pengcheng
Huang, Fen
Fan, Zhiping
Yin, Zhao
Xuan, Li
Lin, Ren
Jiang, Xuejie
Yu, Guopan
Liu, Qifa
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[2] Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study
Yu, Guopan
Zhang, Yu
Yu, Sijian
Yin, Zhao
Weng, Guangyang
Xu, Na
Du, Xin
Lin, Dongjun
Xiao, Jie
Sun, Zhiqiang
Zhang, Hongyu
Liang, Xinquan
Guo, Ziwen
Zhao, Weihua
Dai, Min
Fan, Zhiping
Xuan, Li
Liu, Hui
Xu, Dan
Ye, Jieyu
Jiang, Xuejie
Shi, Pengcheng
Jin, Hua
Liu, Qifa
CLINICAL CANCER RESEARCH, 2025, 31 (01) : 87 - 97
[3] Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study
Yu, Sijian
Zhang, Yu
Yu, Guopan
Wang, Yu
Shao, Ruoyang
Du, Xin
Xu, Na
Lin, Dongjun
Zhao, Weihua
Zhang, Xiong
Xiao, Jie
Sun, Zhiqiang
Deng, Lan
Liang, Xinquan
Zhang, Hongyu
Guo, Ziwen
Dai, Min
Shi, Pengcheng
Huang, Fen
Fan, Zhiping
Liu, Qiong
Lin, Ren
Jiang, Xuejie
Xuan, Li
Liu, Qifa
Jin, Hua
JOURNAL OF INTERNAL MEDICINE, 2024, 295 (02) : 216 - 228
[4] Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Konopleva, Marina Y.
Dail, Monique
Daver, Naval G.
Garcia, Jacqueline S.
Jonas, Brian A.
Yee, Karen W. L.
Kelly, Kevin R.
Vey, Norbert
Assouline, Sarit
Roboz, Gail J.
Paolini, Stefania
Pollyea, Daniel A.
Tafuri, Agostino
Brandwein, Joseph M.
Pigneux, Arnaud
Powell, Bayard L.
Fenaux, Pierre
Olin, Rebecca L.
Visani, Giuseppe
Martinelli, Giovanni
Onishi, Maika
Wang, Jue
Huang, Weize
Dunshee, Diana R.
Hamidi, Habib
Ott, Marion G.
Hong, Wan-Jen
Andreeff, Michael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 364 - 374
[5] A Phase I Study of Pevonedistat, Azacitidine and Venetoclax for Patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML)
Murthy, Guru Subramanian Guru
Kaufmann, Scott H.
Szabo, Aniko
Harrington, Alexandra M.
Michaelis, Laura C.
Abedin, Sameem
Carlson, Karen
Runaas, Lyndsey
Longo, Walter L.
Hinman, Alexander
Maldonado-Schmidt, Sonia
Thomas, Althea
Baim, Arielle
Litzow, Mark R.
Atallah, Ehab L.
BLOOD, 2021, 138
[6] Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial
Cao, Han-Yu
Chen, Lu-Lu
Wan, Chao-Ling
Hu, Xiao-Hui
Wu, Bing
Yang, Li
Wang, Li
Zhang, Yang
Wu, De-Pei
Dai, Hai-Ping
Zhang, Hao
Xue, Shengli
BLOOD, 2023, 142
[7] Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed/Refractory Acute Myeloid Leukemia
Yu, Guopan
Xu, Na
Huang, Fen
Fan, Zhiping
Liu, Hui
Shi, Pengcheng
Zhou, Hongsheng
Wang, Zhixiang
Zhang, Yu
Liu, Qifa
BLOOD, 2020, 136
[8] Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higherrisk myelodysplastic syndrome (MDS).
Desikan, Sai Prasad
Montalban-Bravo, Guillermo
Ohanian, Maro
Daver, Naval Guastad
Kadia, Tapan M.
Venugopal, Sangeetha
Chien, Kelly Sharon
Kanagal-Shamanna, Rashmi
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study
You, Liangshun
Liu, Yi
Mai, Wenyuan
Xie, Wanzhuo
Zhou, De
Mao, Liping
Chen, Lili
Zhou, Xinping
Ma, Liya
Zheng, Xiaolong
Wei, Juying
Lou, Yinjun
Ye, Xingnong
Tong, Hongyan
Jin, Jie
Meng, Haitao
EUROPEAN JOURNAL OF CANCER, 2024, 202
[10] A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation
Desikan, Sai Prasad
Ravandi, Farhad
Pemmaraju, Naveen
Konopleva, Marina
Loghavi, Sanam
Borthakur, Gautam
Jabbour, Elias J.
Daver, Naval
Jain, Nitin
Chien, Kelly S.
Maiti, Abhishek
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Kwari, Monica
Kantarjian, Hagop
Short, Nicholas J.
BLOOD, 2021, 138

← 1 2 3 4 5 →